ClinicalTrials.gg
RecruitingNCT03579836Updated Mar 10, 2025

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

A Phase 1/2 interventional study of BEY1107 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer, sponsored by BeyondBio Inc.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by BeyondBio Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2018; still recruiting 8 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of — 43 open to participants now, 63 under way, 10 of them phase 3. Pancreatic Neoplasms · Korea, Republic of.

Planned enrollment
96th of 164
75 · median 100
Started
2018
with 14 others
Phase 1/2
14 of 198
4 open now
Primary completion
2026-11
later than 23 of 62 live
Registered
91st of 198
by date

Among the 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of, this one is the 96th largest by planned enrollment of the 164 interventional ones that give a count, is one of 15 that started in 2018, is one of 14 in phase 1/2, reaches primary completion later than 23 of the 62 other live ones, and was the 91st registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

43 of the 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.

Read the detailed description

The key purpose of the main part of the study is to assess the MTD, safety and efficacy of BEY1107 as monotherapy and combination therapy for locally advanced and/or metastatic pancreatic cancer. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of BEY1107, to determine the MTD.

Patient will receive BEY1107 for 4 weeks in monotherapy for each cohort (administered in a 3-weeks-on / 1-week-off) during Phase I-1 trial.

At next stage, patient will receive BEY1107 with gemcitabine for 4weeks in phase I-2 trial.

Final stage, patient will receive BEY1107 with gemcitabine for 24weeks in phase II trial.

Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival of fresh biopsy tissue will also be collected for biomarker analysis.

03

Conditions studied

  • Locally Advanced or Metastatic Pancreatic Cancer

Keywords

  • Pancreatic Cancer
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or Cytologically confirmed with pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas
  2. At lease one according to v.1.1
  3. (ECOG) 0,1 or 2
  4. Over 12 weeks of
  5. Adequate Bone marrow, Renal and Liver function at screening

Exclusion criteria

Exclusion criteria :

  1. A patient who has treatment history with locally advanced and/or pancreatic cancer
  2. Major surgery history at screening
  3. Uncontrolled evidence
  4. Active bacterial infection patients
  5. Malignant tumor other than basal cell carcinoma, cervix carcinoma in situ and papillary thyroid cancer
  6. expected Pregnant or breast-feeding patients
  7. , Active or C infection
  8. A patient who has with BEY1107 or Gemcitabine
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Phase I-1 (#4 Cohort)

    BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)

    Drug: BEY1107

  • Experimental
    Phase I-2 (#3 Cohort)

    BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)

    Drug: BEY1107 · Combination Product: Gemcitabine

  • Experimental
    Phase II (#1 Cohort)

    BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks (administered on a 3-week-on and 1-week-off)

    Drug: BEY1107 · Combination Product: Gemcitabine

Interventions

  • DrugAvotaciclibStudies of AvotaciclibAvotaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.

  • Combination productGemcitabine

    Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.

06

What researchers measure

Primary outcomes

  1. MTD & Safety assessment (Phase I)

    Time frame: 0

  2. DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II)

    Time frame: 0

Secondary outcomes

  1. AUC in BEY1107 monotherapy and Gemcitabine combination (Phase I)

    Time frame: 0

  2. Cmax in BEY1107 monotherapy and Gemcitabine combination (Phase I)

    Time frame: 0

  3. DCR(Disease Control Rate) in BEY1107 monotherapy and Gemcitabine combination (Phase I)

    Time frame: 0

  4. ORR(Objective Response Rate) in BEY1107 and Gemcitabine combination (Phase II)

    Time frame: 0

  5. Number of subjects with Adverse events in BEY1107 and Gemcitabine combination (Phase II)

    Time frame: 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Nov 2026, 102 months after the start.

Of 114 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 102 months is above that.

Counting every sponsor, half of 209 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2018
First posted
Jul 9, 2018
StartActual
May 14, 2018
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03579836
Lead sponsor
BeyondBio Inc.
Responsible party
Sponsor
First posted
Jul 9, 2018
Start date
May 14, 2018
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 10, 2025

Study contacts

BeyondBio Inc.
Contact
clinicaltrials@beyondbio.co.kr
+82-42-716-0020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avotaciclib

Start the discussion